Dakota Wealth Management Has $16.45 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Dakota Wealth Management boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 84,177 shares of the company’s stock after purchasing an additional 1,492 shares during the quarter. Dakota Wealth Management’s holdings in Zoetis were worth $16,446,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Webster Bank N. A. raised its position in shares of Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares during the last quarter. Quarry LP raised its holdings in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares in the last quarter. LRI Investments LLC bought a new stake in shares of Zoetis in the 1st quarter worth approximately $43,000. Central Valley Advisors LLC acquired a new stake in shares of Zoetis during the 2nd quarter worth approximately $49,000. Finally, Future Financial Wealth Managment LLC bought a new stake in shares of Zoetis during the first quarter valued at approximately $51,000. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 4.0 %

NYSE ZTS opened at $181.52 on Friday. The stock’s 50 day simple moving average is $189.23 and its 200 day simple moving average is $177.58. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The firm has a market cap of $82.24 billion, a PE ratio of 35.52, a price-to-earnings-growth ratio of 2.94 and a beta of 0.89. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.41 earnings per share. As a group, sell-side analysts forecast that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.95%. Zoetis’s dividend payout ratio (DPR) is currently 33.86%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. BTIG Research lifted their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. JPMorgan Chase & Co. upped their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Piper Sandler raised their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus upped their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.